DMO study shows robust efficacy of intravitreal dexamethasone implant
April 16th 2021In a real-world study of patients with treatment-naïve and previously treated diabetic macular oedema, injection of intravitreal dexamethasone 0.7-mg implant provided effective disease control with initial and repeat injections, regardless of reinjection interval.
The quest for topical treatments for the posterior segment
April 14th 2021Topical eye drop treatments for the posterior segment would offer easier, less invasive options than those currently available. This would reduce the burden on both patients and their caregivers, increasing adherence and improving outcomes.
Precision management to revolutionise glaucoma diagnosis and treatment
March 26th 2021Artificial intelligence and genetic testing are expected to facilitate choosing the best treatment for each unique glaucoma patient within the next decade. This will not only lead to the best outcomes for individuals but will also spare them the costs and side effects of suboptimal treatments.
Study targets strategies for CI-DMO
March 22nd 2021In the DRCR Retina Network Protocol V, which studied management strategies for eyes with centre-involving DMO and good visual acuity, the majority of eyes randomly assigned to initial observation completed the 2-year study without needing anti-VEGF therapy for vision loss and nearly one-third had spontaneous resolution of DMO.
Cyclosporine options for dry eye relief have varying tolerabilities
March 10th 2021Cyclosporine for dry eye disease appears to be efficacious at all levels and the choice of which formulation to use usually depends on tolerability and affordability. Tolerability hinges primarily on the vehicle, which varies among different products.
Brolucizumab for neovascular AMD: Safety guidance and clinician perspectives
March 3rd 2021Although the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.
Investigators find genetic factors may influence diabetic eye disease
March 1st 2021Study results, including data from approximately 42,000 eyes, found diabetic retinopathy severity is a risk factor for diabetic eye disease progression. Other findings support the idea that genetic factors may influence the development of proliferative diabetic retinopathy versus diabetic macular oedema.
Navigating COVID-19 with ophthalmic patients in the hospital setting
February 22nd 2021Experience at one ophthalmic practice in Bulgaria demonstrates that new operating procedures, technologies and good management can enable clinics to remain open and operate safely during the COVID-19 pandemic. Ophthalmic training and education should continue to be a priority.
Biophytis expands patient recruitment for part II of COVA Study in France, Belgium
February 17th 2021Biophytis will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing its leading drug candidate as a potential treatment for acute respiratory failure linked to COVID-19.
Investigators explore pathogenic cytokines as biomarkers for DMO
January 27th 2021Results of a study analysing cytokine levels in the aqueous humour and serum of patients with nonproliferative diabetic retinopathy with and without diabetic macular oedema support further research investigating transforming growth factor-β-induced Gene Human Clone 30 (BIGH3) as a potential biomarker for DMO.